Myosin-Va Contributes to Manifestation of Malignant-Related Properties in Melanoma Cells by Alves, Cleidson P. et al.
 
Myosin-Va Contributes to Manifestation of Malignant-Related
Properties in Melanoma Cells
 
 
(Article begins on next page)
The Harvard community has made this article openly available.
Please share how this access benefits you. Your story matters.
Citation Alves, Cleidson P., Milene H. Moraes, Josane F. Sousa, Carmen
Lucia S. Pontes, Anelisa Ramão, Satoru Yokoyama, Daniel M.
Trindade, David E. Fisher, and Enilza M. Espreafico. 2013.
“Myosin-Va Contributes to Manifestation of Malignant-Related
Properties in Melanoma Cells.” The Journal of investigative
dermatology 133 (12): 10.1038/jid.2013.218.
doi:10.1038/jid.2013.218. http://dx.doi.org/10.1038/jid.2013.218.
Published Version doi:10.1038/jid.2013.218
Accessed February 16, 2015 10:16:21 AM EST
Citable Link http://nrs.harvard.edu/urn-3:HUL.InstRepos:12406541
Terms of Use This article was downloaded from Harvard University's DASH
repository, and is made available under the terms and conditions
applicable to Other Posted Material, as set forth at
http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-
use#LAAMyosin-Va Contributes to Manifestation of Malignant-Related
Properties in Melanoma Cells
Cleidson P. Alves1, Milene H. Moraes1, Josane F. Sousa1, Carmen Lucia S. Pontes1,
Anelisa Ramão1, Satoru Yokoyama3, Daniel M. Trindade1,4, David E. Fisher2, and Enilza M.
Espreafico1,*
1Department of Cellular and Molecular Biology and Pathogenic Bioagents, Faculty of Medicina of
Ribeirão Preto, University of São Paulo, 14049-900, Ribeirão Preto, São Paulo, Brazil.
2Department of Dermatology, Cutaneous Biology Research Center, Mass. General Hospital,
Harvard Medical School, MA 02115, USA
3Division of Pathogenic Biochemistry, Institute of Natural Medicine, University of Toyama,
Toyama, Japan
TO THE EDITOR
Melanoma is a highly metastatic and therapeutically resistant cancer, whose incidence has
more than tripled in the last decades (Smalley et al., 2010). Physiologically, melanocytes
produce and store melanin pigments in the melanosomes, which are transported to the cell
periphery and transferred to keratinocytes, a process that requires the tripartite complex
Rab27a/melanophilin/myosin-Va (Hume and Seabra, 2011). Myosin-Va is an actin-based
molecular motor that also serves a multitude of other functions, such as plasma membrane
receptor recycling, exocytosis, association with nuclear speckles and the centrosome (see
Woolner and Bement, 2010); interaction with PTEN, thereby modulating PI3K pathway
(van Diepen et al., 2009), interaction with Bcl-xL, proposed to promote invasion of islet-
tumor cells (Du et al., 2007); as biomarker of invasiveness for nonfunctioning pituitary
adenomas (Galland et al., 2010). Moreover, myosin-Va was shown to be up-regulated by
Snail to promote cancer cell invasion (Lan et al., 2010), and was postulated to control
apoptosis by sequestering the pro-apoptotic protein Bmf, which is unleashed upon loss of
cell attachment (Puthalakath et al., 2001).
Up-regulation of MYO5A gene in melanoma and other cancer types was revealed in
different microarray studies compiled here (Table S1; Figure S1). However, these data did
not clarify whether MYO5A up-regulation was associated with melanocyte transformation
or simply reflected tissue specificity since comparison was against normal skin and
melanocytes are minor cells in the skin. Here, we extended this evidence by showing that
MYO5A is up-regulated in a variety of melanoma cell lines in comparison with primary
melanocytes (Figure 1a), as well as in metastatic cells in comparison to paired vertical
growth phase cells (Figure 1b and S2), implicating myosin-Va in malignant transformation
and/or melanoma progression. Interestingly, in this WM panel, myosin-Va expression
correlated with that of the oncogenic transcription factor MITF (Sousa and Espreafico,
2008).
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tTo investigate the role of myosin-Va in melanoma cells, we knocked down this protein
using three different shRNAs (shMYO5A#1-3) carried by lentiviral vectors (Figure S3 and
Qin et al., 2003) and an siRNA (siMYO5A). Once efficient knockdown was attained
(Figures 1c-e), functional studies were performed. Upon adhesion to fibronectin-coated
glass coverslips, MYO5A-depleted cells showed numerous small blebs on their surface and
reduced lamellipodia/filopodia formation (Figure 1f), besides deficient adhesion (Figure 1g)
and spreading (Figure 1h).
Next, we examined the role of myosin-Va in adhesion-independent growth. The ability to
form colony in soft agar, as analyzed after 25-30 days of incubation, was at least 50% lower
for MYO5A-depleted cells than controls, for the three different shRNAs used (Figure 2a).
Proliferation rates under adherent conditions were determined by crystal violet staining for
WM1617 (Figure 2b) or ATP measurements for UACC-257 (Figure 2f), and no differences
were observed, in the time courses analyzed, between MYO5A-knockdown and control
cells. Subsequently, we analyzed transwell migration and invasion and found rates 50 to
70% lower for shMYO5A#2/3-transfected WM1617 cells than controls (Figure 2c). Similar
decrease in transwell invasion was observed for siMYO5A-transfected UACC-257 cells
(Figure 2e). Next, we performed spheroid assays (as in Smalley and Herlyn, 2008) with
shMYO5A#1-transduced cells. Compact spheroids with intact appearance were added to a
tri-dimensional collagen gel and imaged after 24 and 48 hours of culture. Myosin-Va-
depleted cells exhibited migration distances from spheroid margin to invasion front 50 to
60% shorter than controls (Figure 2d). Also, knockdown cells that migrated out of the
spheroids looked smaller than controls after 48 hours, suggesting that myosin-Va-depleted
cells differ in the sensitivity to microenvironment factors during migration in collagen
matrix.
The multifunctional character of myosin-Va makes us believe that this molecular motor, in
addition to its role in cell adhesion/motility by promoting focal adhesion dynamics and
filopodia/lamillipodia growth (supported by work in progress from our group, Nader et al.),
may also perform a role in extracellular matrix proteolysis, mediating surface exposure and
positioning of matrix metalloproteinases. Indeed, the alignment of metalloproteinases along
the cytoskeleton seems to be a prerequisite for cell invasion in melanoma. Also, co-
localization of metalloproteinases with myosin-Va (Sbai et. al., 2011) in astrocytes, and a
role for RAB27A (Bobrie et al., 2012) in the release of metalloproteinase-9 to promote
metastasis of mammary carcinoma cells have been shown. Moreover, evidence that
RAB27A (Akavia et al., 2010) functions as a driver of cancer supports the hypothesis that,
likewise, myosin-Va promotes malignancy by functioning in vesicular trafficking. Indeed,
endocytosis and recycling of plasma membrane receptors require Rab GTPases and
molecular motors with reflexes in adhesion dynamics, cell signaling and metabolism in
many instances shown to drive oncogenic transformation and invasion (Mosesson et al.,
2008). Furthermore, the relevance of our findings is supported by recent report
demonstrating that the formation of filopodia is a critical step in the metastasis cascade
(Shibue, et. al., 2013).
Additionally, we cannot rule out the possibility that some of the effects observed could be
due to an increase in the rates of apoptosis in the MYO5A knockdown cells. Although we
have not observed alteration of viability after myosin-Va depletion in short term culturing
under regular conditions, increase of apoptosis rates under adhesion blockage and poor
recovery of frozen stocks were noted. In fact, recent independent findings reinforce
participation of myosin-Va in the control of apoptosis. Bmf sequestration to the actin
cytoskeleton, presumably in complex with myosin-Va/DLC2, promotes resistance to MEK-
inhibitors (Van Brocklin et al., 2009). Accordingly, overexpression of myosin-Va tail
fragments harboring the binding site for DLC2 leads to apoptosis in melanoma cells likely
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tby disrupting Bmf and probably also Bim anchorage (Izidoro-Toledo and Borges et. al.,
2013). Finally, miR-145, which is a transcriptional target of p53 and known to act as a tumor
suppressor, was recently shown to target myosin-Va (Dynoodt et. al., 2012). Therefore,
myosin-Va may integrate mechanisms that interconnect invasion/migration machinery and
resistance to apoptosis. Interdependencies between these processes are reviewed in
Alexander and Friedl (2012).
In summary, the data presented here show that myosin-Va promotes adhesion dynamics,
anchorage-independent survival, migration and invasion in vitro. Therefore, up-regulation of
myosin-Va during melanoma progression may be part of a general mechanism that promotes
malignant properties.
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tFigure 1. Myosin-Va is highly expressed in melanoma cells and its knockdown impairs cell
adhesion and spreading on fibronectin-coated surface
(a) Relative MYO5A mRNA expression detected by qPCR in melanocytes (pMel1 to 4)
versus melanoma cells, using β -actin for normalization and mean of all melanocytes as
reference value. (b) Western-blot of myosin-Va in a panel of melanoma cell lines of radial
growth phase (RGP), vertical growth phase (VGP) and metastasis (M), including two
genetic pairs (WM793 and 1205Lu; WM278 and WM1617). (c-e) Western-blots for
myosin-Va in (c, d) WM1617 and (e) UACC-257. WM1617 cells were lysed 3 days after
transduction with lentiviral vectors carrying shRNAs targeted to bacterial Lac-Z (shControl)
or MYO5A (shMYO5A#1), or after stable selection with antibiotics for about 2-3 weeks in
the case of shMYO5A#2-3 and respective shControl (Figure S3). UACC-257 cells were
lysed 3 days after transfection with siRNA against myosin-Va or control. (f) Confocal
images of F-actin stained cells adhered to fibronectin-coated coverslips for the indicated
times. Arrows indicate transduced cells visualized by GFP expression (inserts). Scale bar =
20μ m. (g) Cells allowed to adhere on fibronectin-coated surface for the indicated times were
counted and data were plotted as mean ± SD from 3 independent experiments. (h) Cell
spreading. Imaged as in (f) and the areas for 60 cells/time point were measured using
ImageJ.
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tFigure 2. Ablation of myosin-Va inhibits colony formation, migration and invasiveness of
metastatic melanoma cells without affecting cell proliferation
(a-c) Lentiviral transduced WM1617 cells, using three independent shMYO5A or
shControls, were used to assess: (a) Colony formation in soft-agar after 30 days of growth.
Scale bar = 500μ m; (b) Proliferation rates by absorbance measurement of crystal violet
staining; (c) Migration in transwell and invasion in transwell-matrigel assay. Cells were kept
in starvation conditions 24 hour prior the assay and were then allowed to migrate/invade for
24 hours. Scale bar = 50μ m. (d) Migration in 3D collagen. After 24 or 48 hours of
incubation - distance from spheroid edge to invasive front was measured and the data from
three independent experiments were plotted as a percentage of control. Scale bar = 100μ m.
(e-f) Transwell invasion and proliferation rates of UACC257 cells transiently transfected
with duplex siRNA targeted to MYO5A and irrelevant siRNA. Invasion assay was done as
described in c, and proliferation rates were estimated based on ATP measurements. Data
were plotted as mean ± SD from 3 independent experiments. Scale bar = 50μ m.
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